Ademi LLP is investigating Syneos Health (Nasdaq: SYNH) for possible breaches of fiduciary duty and other violations of law in its transaction with the Investment Consortium.
Syneos Health stockholders are expected to receive only $43.00 per share in cash in a transaction valued at approximately $7.1 billion, including outstanding debt. The transaction agreement unreasonably limits competing bids for Syneos Health by imposing a significant penalty if Syneos Health accepts a superior bid. Syneos Health insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Syneos Health’s board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Syneos Health.